Abstract
Background: There is growing evidence to suggest a significant role for the adaptive immune system in disease progression and relapse. Therapies targeted the inflammatory responses of epidermal and immune system cells have been demonstrated effect in the treatment of vitiligo. However, more comparative studies are needed to inform the treatment decision making process. Purpose: To discuss the new target therapies modalities which are currently being trialled or recently licenced for the treatment of vitiligo. Method: A semi structured, rapid systematic review of the literature, where the findings from 11 studies was narratively discussed. Findings: The reviewed medications (ruxolitinib, baritininb, tofacitinib, ritlecitinib, afamelanotide, crisaborole and apremilast) all showed reduction in the percentage of depigmented body surface area and were well tolerated. However, no head-to-head studies were identified to compare the medications to each other or to other treatment modalities used in the treatment of vitiligo, to determine superiority.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
